Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Odanacatib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK known ✓ | P43235 | 16/20 | 1.00 |
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSB | P07858 | 7/20 | 1.00 |
| ▸ | CTSS | P25774 | 5/20 | 1.00 |
| ▸ | CTSF | Q9UBX1 | 3/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odanacatib SCHEMBL1496266 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL3479347 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL15827397 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL2155573 | 0.94 | CTSK (0.90) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL21828714 | 0.94 | CTSK (0.88) | CTSKCTSLCTSBCTSSCTSF | |
| Odanacatib SCHEMBL21828716 | 0.94 | CTSK (0.88) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL2155279 | 0.94 | CTSK (0.88) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL2156790 | 0.92 | CTSK (0.85) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL22733918 | 0.91 | CTSK (0.83) | CTSKCTSLCTSBCTSSCTSF | |
| SCHEMBL22733917 | 0.91 | CTSK (0.83) | CTSKCTSLCTSBCTSSCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4046987-B1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2025-08-27 | — | — | EP | disclosed |
| US-12371400-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-07-29 | — | — | US | disclosed |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240182409-A1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2024-06-06 | — | — | US | disclosed |
| US-11820734-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-11-21 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11459340-B2 | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-4046987-A1 | CATHEPSIN INHIBITORS | Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) | 2022-08-24 | — | — | EP | disclosed |
| US-20220227705-A1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2022-07-21 | — | — | US | disclosed |
| EP-3720840-B1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-01-19 | — | — | EP | disclosed |
| US-11174224-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2021-11-16 | — | — | US | disclosed |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200385341-A1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2020-12-10 | — | — | US | disclosed |
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| WO-2020063821-A1 | POLYPEPTIDE CONJUGATE OF ODN OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京和理咨询有限公司 | 2020-04-02 | — | — | WO | disclosed |
| EP-2709602-B1 | USE OF CATHEPSIN K INHIBITION FOR THE TREATMENT AND/OR PROPHYLAXIS OF PULMONARY HYPERTENSION AND/OR HEART FAILURE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017030983-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820734-B2 | Cathepsin inhibitors | CTSK, CTSZ, CTSF | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
| US-20200277308-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | CTSK 3020/4885CTSL 4361/4885CTSB 3422/4885 |
| US-12371400-B2 | Cathepsin inhibitors | CTSK, CTSZ, CTSF | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | CTSK 816/4885CTSL 1936/4885CTSB 2013/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | CTSK 816/4885CTSL 1936/4885CTSB 2013/4885 |
| US-10894797-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors | SRC, PTPRCAP, PTPRC | CTSK 3020/4885CTSL 4361/4885CTSB 3422/4885 |
| US-11034705-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | CTSK 2815/4885CTSL 4138/4885CTSB 3133/4885 |
| US-20200115389-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | SRC, PTPRCAP, PTPRC | CTSK 3020/4885CTSL 4361/4885CTSB 3422/4885 |
| US-11459340-B2 | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors | SRC, PTPRCAP, PTPN2 | CTSK 3441/4885CTSL 4305/4885CTSB 3559/4885 |
| US-20200385341-A1 | CATHEPSIN INHIBITORS | CTSK, CTSZ, CTSF | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
| US-11174224-B2 | Cathepsin inhibitors | CTSK, CTSZ, CTSF | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
| US-20210040122-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | CTSK 2815/4885CTSL 4138/4885CTSB 3133/4885 |
| US-20220227705-A1 | CATHEPSIN INHIBITORS | CTSK, CTSZ, CTSF | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
| US-20240182409-A1 | CATHEPSIN INHIBITORS | CTSK, CTSZ, CTSF | CTSK 1/4885CTSL 12/4885CTSB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.